Cullinan Therapeutics, Inc. announced on November 14, 2024, that it would present new preclinical data for CLN-978, its novel CD19xCD3 T cell engager, at the American College of Rheumatology (ACR) Convergence 2024. The presentation, scheduled for November 16, 2024, detailed in vitro preclinical data supporting the broad clinical development of CLN-978 in autoimmune diseases.
The new data demonstrated that CLN-978 induced similar T cell activation, target B cell depletion, and cytokine production in human peripheral blood mononuclear cells (PBMC) derived from patients with systemic lupus erythematosus (n=12) or rheumatoid arthritis (n=9) compared to healthy volunteers (n=11). These findings suggest that the cytokine window observed in B-NHL model systems is expected to be preserved in SLE and RA patients, indicating a potentially broad therapeutic index.
These preclinical results reinforce CLN-978's potential as a highly potent T cell engager capable of deep B cell depletion with off-the-shelf convenience and subcutaneous delivery. The company expects initial clinical data from the global Phase 1b clinical trial in SLE in the fourth quarter of 2025, following regulatory clearances in the U.S. and Australia.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.